ICOS costimulation in inflammatory bowel disease

Takanori Kanai, Teruji Totsuka, Katsunari Tezuka, Mamoru Watanabe

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

For years, medical researchers have striven to develop selective immunotherapies that could specifically ameliorate pathogenic immune responses without immunocompromising the patient. Blockade of many known receptors on T cells can inhibit the initiation of immune responses. However, this approach is problematic in that it is not possible to predict the onset of disease in patients. Current immunotherapies are unsatisfactory for the sporadic exacerbating type of diseases such as multiple sclerosis and inflammatory bowel disease (IBD), because they require either long-term treatment or acute treatment with high-dose immunosuppressants. With regard to this issue, the inducible and inflammatory site-specific molecule, inducible costimulator (ICOS), may be particularly useful as an ideal targeting molecule for the strategy of treatment of human IBD patients.

Original languageEnglish
Pages (from-to)78-81
Number of pages4
JournalJournal of Gastroenterology
Volume37
Issue numberSUPPL. 14
Publication statusPublished - 2002 Nov 1
Externally publishedYes

Fingerprint

Inducible T-Cell Co-Stimulator Protein
Inflammatory Bowel Diseases
Immunotherapy
Immunosuppressive Agents
T-Cell Antigen Receptor
Multiple Sclerosis
Therapeutics
Research Personnel

Keywords

  • Crohn's disease
  • ICOS/AILIM
  • Murine
  • Th1

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Kanai, T., Totsuka, T., Tezuka, K., & Watanabe, M. (2002). ICOS costimulation in inflammatory bowel disease. Journal of Gastroenterology, 37(SUPPL. 14), 78-81.

ICOS costimulation in inflammatory bowel disease. / Kanai, Takanori; Totsuka, Teruji; Tezuka, Katsunari; Watanabe, Mamoru.

In: Journal of Gastroenterology, Vol. 37, No. SUPPL. 14, 01.11.2002, p. 78-81.

Research output: Contribution to journalArticle

Kanai, T, Totsuka, T, Tezuka, K & Watanabe, M 2002, 'ICOS costimulation in inflammatory bowel disease', Journal of Gastroenterology, vol. 37, no. SUPPL. 14, pp. 78-81.
Kanai T, Totsuka T, Tezuka K, Watanabe M. ICOS costimulation in inflammatory bowel disease. Journal of Gastroenterology. 2002 Nov 1;37(SUPPL. 14):78-81.
Kanai, Takanori ; Totsuka, Teruji ; Tezuka, Katsunari ; Watanabe, Mamoru. / ICOS costimulation in inflammatory bowel disease. In: Journal of Gastroenterology. 2002 ; Vol. 37, No. SUPPL. 14. pp. 78-81.
@article{99f8fbbd720149a3a79290456aa3203a,
title = "ICOS costimulation in inflammatory bowel disease",
abstract = "For years, medical researchers have striven to develop selective immunotherapies that could specifically ameliorate pathogenic immune responses without immunocompromising the patient. Blockade of many known receptors on T cells can inhibit the initiation of immune responses. However, this approach is problematic in that it is not possible to predict the onset of disease in patients. Current immunotherapies are unsatisfactory for the sporadic exacerbating type of diseases such as multiple sclerosis and inflammatory bowel disease (IBD), because they require either long-term treatment or acute treatment with high-dose immunosuppressants. With regard to this issue, the inducible and inflammatory site-specific molecule, inducible costimulator (ICOS), may be particularly useful as an ideal targeting molecule for the strategy of treatment of human IBD patients.",
keywords = "Crohn's disease, ICOS/AILIM, Murine, Th1",
author = "Takanori Kanai and Teruji Totsuka and Katsunari Tezuka and Mamoru Watanabe",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "37",
pages = "78--81",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "SUPPL. 14",

}

TY - JOUR

T1 - ICOS costimulation in inflammatory bowel disease

AU - Kanai, Takanori

AU - Totsuka, Teruji

AU - Tezuka, Katsunari

AU - Watanabe, Mamoru

PY - 2002/11/1

Y1 - 2002/11/1

N2 - For years, medical researchers have striven to develop selective immunotherapies that could specifically ameliorate pathogenic immune responses without immunocompromising the patient. Blockade of many known receptors on T cells can inhibit the initiation of immune responses. However, this approach is problematic in that it is not possible to predict the onset of disease in patients. Current immunotherapies are unsatisfactory for the sporadic exacerbating type of diseases such as multiple sclerosis and inflammatory bowel disease (IBD), because they require either long-term treatment or acute treatment with high-dose immunosuppressants. With regard to this issue, the inducible and inflammatory site-specific molecule, inducible costimulator (ICOS), may be particularly useful as an ideal targeting molecule for the strategy of treatment of human IBD patients.

AB - For years, medical researchers have striven to develop selective immunotherapies that could specifically ameliorate pathogenic immune responses without immunocompromising the patient. Blockade of many known receptors on T cells can inhibit the initiation of immune responses. However, this approach is problematic in that it is not possible to predict the onset of disease in patients. Current immunotherapies are unsatisfactory for the sporadic exacerbating type of diseases such as multiple sclerosis and inflammatory bowel disease (IBD), because they require either long-term treatment or acute treatment with high-dose immunosuppressants. With regard to this issue, the inducible and inflammatory site-specific molecule, inducible costimulator (ICOS), may be particularly useful as an ideal targeting molecule for the strategy of treatment of human IBD patients.

KW - Crohn's disease

KW - ICOS/AILIM

KW - Murine

KW - Th1

UR - http://www.scopus.com/inward/record.url?scp=0036854764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036854764&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 78

EP - 81

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - SUPPL. 14

ER -